SCHEMBL2052096

SCHEMBL2052096

O=C1C=CC2=NCN=CC2=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9905244 0.69
SCHEMBL4753278 0.67 ALDH1A1 (0.32)
SCHEMBL935394 0.60
SCHEMBL31722845 0.51 MAOA (0.33)
SCHEMBL12570784 0.51 MAOA (0.41)
Benzoquinone SCHEMBL460082 0.51 ALDH1A1 (1.00)
Benzoquinone SCHEMBL30679171 0.51
SCHEMBL538982 0.48
Benzoquinone SCHEMBL3235600 0.48 ALDH1A1 (0.89)
Benzoquinone SCHEMBL3394588 0.48

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1507776-A1 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS Amgen Inc. (US) 2005-02-23 EP claimed
WO-2003101985-A1 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS AMGEN INC. (US) 2003-12-11 WO claimed
US-12162893-B2 Tricyclic pyridones and pyrimidones ERASCA, INC. (US) 2024-12-10 US disclosed
CN-118076612-A Sulfur-containing heteroaromatic tricyclic KRAS inhibitors 医睿世康药业研发公司 2024-05-24 CN disclosed
CN-220933309-U Display panel TCL华星光电技术有限公司 2024-05-10 CN disclosed
EP-4347603-A1 SULFUR-CONTAINING HETEROAROMATIC TRICYCLIC KRAS INHIBITORS Erasca, Inc. (US) 2024-04-10 EP disclosed
WO-2023183755-A1 TRICYCLIC PYRIMIDONES ERASCA, INC. (US) 2023-09-28 WO disclosed
CN-116615428-A Tricyclic pyridones and pyrimidinones 医睿世康药业研发公司 2023-08-18 CN disclosed
CN-116547280-A Benzo [ h ] quinazolin-4-amine and thieno [3,2-h ] quinazolin-4-amine derivatives for the treatment of cancer 雷多纳治疗公司 2023-08-04 CN disclosed
EP-4217071-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES Erasca, Inc. (US) 2023-08-02 EP disclosed
CN-113563272-B Preparation method of 2-phenylquinazolinone compound 三峡大学 2023-03-10 CN disclosed
US-20220119409-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2022-04-21 US disclosed
EP-3938367-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES Merck Patent GmbH (DE) 2022-01-19 EP disclosed
WO-2020182779-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2020-09-17 WO disclosed
WO-2012170845-A2 METABOTROPIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF HEFFERNAN MICHELE L R (US) 2012-12-13 WO disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed
EP-1846410-A2 DIHYDROQUINAZOLINONES AS 5HT MODULATORS Bristol-Myers Squibb Company (US) 2007-10-24 EP disclosed
WO-2006086464-A2 DIHYDROQUINAZOLINONES AS 5HT MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-17 WO disclosed
EP-1507776-A1 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS Amgen Inc. (US) 2005-02-23 EP disclosed
WO-2003101985-A1 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS AMGEN INC. (US) 2003-12-11 WO disclosed